Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
erythromycin and benzoyl peroxide
Overview
What is Aktipak?
Aktipak
Saccharopolyspora erythraea
Streptomyces erythreus
Chemically, erythromycin is (CHNO). It has the following structural formula:
Erythromycin has the molecular weight of 733.94. It is a white crystalline powder and has a solubility of approximately 1 mg/mL in water and is soluble in alcohol at 25°C.
Aktipak also contains benzoyl peroxide for topical use. Benzoyl peroxide is an oxidizing agent demonstrating antibacterial activity.
Chemically, benzoyl peroxide is (CHO). It has the following structural formula:
Benzoyl peroxide has the molecular weight of 242.23. It is a white granular powder and is sparingly soluble in water and alcohol and soluble in acetone, chloroform and ether.
Each gram of product, as dispensed, contains 30 mg of erythromycin and 50 mg of benzoyl peroxide in a base of SD Alcohol 40B, purified water, hydroxypropyl cellulose, Carbomer Homopolymer Type B, sodium hydroxide, dioctyl sodium sulfosuccinate 75%. Each Aktipak contains 0.8 grams of product.
What does Aktipak look like?
What are the available doses of Aktipak?
Sorry No records found.
What should I talk to my health care provider before I take Aktipak?
Sorry No records found
How should I use Aktipak?
Aktipak is indicated for the topical treatment of acne vulgaris.
Aktipak requires thorough mixing by the patient immediately prior to each use. The medication should be applied twice daily, morning and evening, or as directed by a physician, to affected areas after the skin is thoroughly washed, rinsed with warm water and gently patted dry.
What interacts with Aktipak?
Aktipak is contraindicated in those individuals who have shown hypersensitivity to any of its components.
What are the warnings of Aktipak?
Sorry No Records found
What are the precautions of Aktipak?
General
For topical use only; not for ophthalmic use. Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating or abrasive agents. If severe irritation develops, discontinue use and institute appropriate therapy.
The use of antibiotic agents may be associated with the overgrowth of nonsusceptible organisms. If this occurs, discontinue use and take appropriate measures.
Avoid contact with eyes and all mucous membranes.
Information for Patients
Patients using Aktipak should receive the following information and instructions:
1. Patients should be informed that they will need to mix this medication prior to use. The medication will be dispensed in one foil pouch which contains medication in two separated compartments.2. The contents must be mixed thoroughly by the patient (in the palm of the hand), prior to application.3. Patients should apply the product immediately after mixing, then the hands should be washed.4. Do not mix or apply near an open flame.5. Aktipak may bleach hair or colored fabric.6. Excessive or prolonged exposure to sunlight should be limited. To minimize exposure to sunlight, a hat or other clothing should be worn.7. This medication is to be used as directed by a physician. It is for external use only. Avoid contact with the eyes, mouth, and all mucous membranes as this product may be irritating.8. Patients should report to their physician any signs of local adverse reactions.9. This medication should not be used for any disorder other than that for which it was prescribed.10. Patients should not use any other topical acne preparation unless otherwise directed by physician.11. Patients should be instructed to review the instructions for use on the product carton.12. This medication should be stored at room temperature away from heat and any open flame.
Carcinogenesis, Mutagenesis, Impairment of Fertility
The combination of benzoyl peroxide and erythromycin in Aktipak has not been evaluated for its carcinogenic or mutagenic potential or for its effects on fertility.
Benzoyl peroxide has been shown to be a tumor promoter and progression agent in a number of animal studies. The clinical significance of this is unknown.
Benzoyl peroxide in acetone at doses of 5 and 10 mg administered twice per week induced skin tumors in transgenic Tg.AC mice in a study using 20 weeks of topical treatment.
Benzoyl peroxide has been found to cause DNA strand breaks in a variety of mammalian cell types, to be mutagenic in tests by some but not all investigators, and to cause sister chromatid exchanges in Chinese hamster ovary cells.
No animal studies have been performed to evaluate the carcinogenic potential or effects on fertility of topical erythromycin. However, long-term (2-year) oral studies in rats with erythromycin base and erythromycin ethylsuccinate and in rats and mice with erythromycin stearate did not provide evidence of tumorigenicity.
The genotoxicity of erythromycin stearate has been evaluated in the reverse mutation assay, the mouse L5178Y lymphoma cell assay, and for sister chromatid exchanges and chromosomal aberrations in CHO cells. These studies indicated that erythromycin stearate was not genotoxic.
There was no apparent effect on male or female fertility in rats fed erythromycin base at levels up to 0.25% of diet.
Pregnancy
Animal reproduction studies have not been conducted with Aktipak or benzoyl peroxide.
There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% diet) prior to and during mating, during gestation and through weaning of two successive litters.
There are no well-controlled trials in pregnant women with Aktipak. It is also not known whether Aktipak can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Aktipak should be given to a pregnant woman only if clearly needed.
Nursing Women
It is not known whether the ingredients of Aktipak are excreted in human milk after topical application. However, erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Therefore, caution should be exercised when erythromycin is administered to a nursing woman.
Pediatric Use
Safety and effectiveness of this product in pediatric patients below 12 years of age have not been established.
What are the side effects of Aktipak?
During clinical trials, 550 acne patients were studied. Of these patients, 236 were treated with Aktipak. The most frequently reported adverse event considered at least possibly related was dry skin (7.6%) as compared to Vehicle (3.9%). Application site reactions (stinging, burning sensation, tingling, erythema) were reported in 2.5% of patients versus 1.3% of Vehicle patients. Blepharitis, pruritus and photosensitivity reactions were reported in <2% of patients who used the dual pouch product.
| DRY SKIN | 18 (7.6%) | 6 (3.9%) | 6 (5.0%) | 0 | |||||
| APPLICATION SITE REACTION(stinging, erythema, and burning) | 6 (2.5%) | 2 (1.3%) | 1 (0.8%) | 0 | |||||
| BLEPHARITIS | 4 (1.7%) | 1 (0.7%) | 0 | 1 (2.5%) | |||||
| PRURITUS | 4 (1.7%) | 2 (1.3%) | 3 (2.5%) | 0 | |||||
| PHOTOSENSITIVITY REACTION(Sunburn, stinging with sun exposure) | 3 (1.3%) | 0 | 0 | 0 | |||||
| PEELING | 1 (0.5%) | 1 (0.7%) | 0 | 0 |
What should I look out for while using Aktipak?
Aktipak is contraindicated in those individuals who have shown hypersensitivity to any of its components.
What might happen if I take too much Aktipak?
Sorry No Records found
How should I store and handle Aktipak?
60 Pouches per carton NDC 70363-007-60Store at Room Temperature 20 to 25°C (68 to 77°F).Keep away from heat and any open flame.Keep out of the reach of children.Rx Only60 Pouches per carton NDC 70363-007-60Store at Room Temperature 20 to 25°C (68 to 77°F).Keep away from heat and any open flame.Keep out of the reach of children.Rx Only60 Pouches per carton NDC 70363-007-60Store at Room Temperature 20 to 25°C (68 to 77°F).Keep away from heat and any open flame.Keep out of the reach of children.Rx Only60 Pouches per carton NDC 70363-007-60Store at Room Temperature 20 to 25°C (68 to 77°F).Keep away from heat and any open flame.Keep out of the reach of children.Rx Only60 Pouches per carton NDC 70363-007-60Store at Room Temperature 20 to 25°C (68 to 77°F).Keep away from heat and any open flame.Keep out of the reach of children.Rx Only
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid. A single dose pharmacokinetic study, involving the application of either one or three units of Aktipak, was performed in 16 adult acne patients to determine systemic absorption of erythromycin. Erythromycin (with a plasma lower limit of quantitation of 2 ng/ml) was not detectable, except in one patient who was in the one unit application group.
Non-Clinical Toxicology
Aktipak is contraindicated in those individuals who have shown hypersensitivity to any of its components.Sulfacetamide preparations are incompatible with silver preparations.
For topical use only; not for ophthalmic use. Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating or abrasive agents. If severe irritation develops, discontinue use and institute appropriate therapy.
The use of antibiotic agents may be associated with the overgrowth of nonsusceptible organisms. If this occurs, discontinue use and take appropriate measures.
Avoid contact with eyes and all mucous membranes.
During clinical trials, 550 acne patients were studied. Of these patients, 236 were treated with Aktipak. The most frequently reported adverse event considered at least possibly related was dry skin (7.6%) as compared to Vehicle (3.9%). Application site reactions (stinging, burning sensation, tingling, erythema) were reported in 2.5% of patients versus 1.3% of Vehicle patients. Blepharitis, pruritus and photosensitivity reactions were reported in <2% of patients who used the dual pouch product.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).